aTyr Pharma will be showcasing a subgroup analysis of the Phase 3 EFZO-FIT™ study of Efzofitimod in pulmonary sarcoidosis at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) conference in 2026. The study is paramount in evaluating the efficacy of Efzofitimod. This analysis will focus on specific subsets of participants, shedding light on the drug's impact. This event is significant as it provides detailed insights from the trial and aids in understanding the drug's performance in treating pulmonary sarcoidosis.